Literature DB >> 11756171

Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.

Jianguo Jin1, Todd M Quinton, Jin Zhang, Susan E Rittenhouse, Satya P Kunapuli.   

Abstract

Adenosine diphosphate (ADP) is a platelet agonist that causes platelet shape change and aggregation as well as generation of thromboxane A(2), another platelet agonist, through its effects on P2Y1, P2Y12, and P2X1 receptors. It is now reported that both 2-propylthio-D-beta gamma-dichloromethylene adenosine 5'-triphosphate (AR-C67085), a P2Y12 receptor-selective antagonist, and adenosine-2'-phosphate-5'-phosphate (A2P5P), a P2Y1 receptor-selective antagonist, inhibited ADP-induced thromboxane A(2) generation in a concentration-dependent manner, indicating that coactivation of the P2Y12 and P2Y1 receptors is essential for this event. SC49992, a fibrinogen receptor antagonist, blocked ADP-induced platelet aggregation and thromboxane A(2) production in a concentration-dependent manner. Similarly, P2 receptor antagonists or SC49992 blocked ADP-induced arachidonic acid liberation. Whereas SC49992 blocked arachidonic acid-induced platelet aggregation, it failed to inhibit thromboxane A(2) generation induced by arachidonic acid. Thus, ADP-induced arachidonic acid liberation, but not subsequent conversion to thromboxane A(2), requires outside-in signaling through the fibrinogen receptor. The Fab fragment of ligand-induced binding site-6 (LIBS6) antibody, which induces a fibrinogen-binding site on the integrin alpha(IIb)beta(3), caused both platelet aggregation and thromboxane A(2) generation. Inhibitors of phosphoinositide 3-kinase, Syk, Src kinases, or protein tyrosine phosphatases inhibited platelet aggregation but not thromboxane A(2) generation, indicating that these signaling molecules have no significant role in phospholipase A(2) activation. In the presence of P2 receptor antagonists A2P5P or AR-C67085, LIBS6 failed to generate thromboxane A(2), suggesting that inside-out signaling through ADP receptors is necessary for this event. It was concluded that both outside-in signaling from the fibrinogen receptor and inside-out signaling from the P2Y1 and P2Y12 receptors are necessary for phospholipase A(2) activation, resulting in arachidonic acid liberation and thromboxane A(2) generation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756171     DOI: 10.1182/blood.v99.1.193

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation.

Authors:  Todd M Quinton; Soochong Kim; Carol Dangelmaier; Robert T Dorsam; Jianguo Jin; James L Daniel; Satya P Kunapuli
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

3.  G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases.

Authors:  Haripriya Shankar; Bryan N Kahner; Janani Prabhakar; Parth Lakhani; Soochong Kim; Satya P Kunapuli
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

4.  Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.

Authors:  Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  Am J Pathol       Date:  2012-05-18       Impact factor: 4.307

5.  Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia.

Authors:  B Nagy; J Jin; B Ashby; M P Reilly; S P Kunapuli
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

6.  P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Authors:  Anneke Bierend; Thomas Rau; Renke Maas; Edzard Schwedhelm; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

7.  Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.

Authors:  Darin A Trier; Kimberly D Gank; Deborah Kupferwasser; Nannette Y Yount; William J French; Alan D Michelson; Leon I Kupferwasser; Yan Q Xiong; Arnold S Bayer; Michael R Yeaman
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

Review 8.  Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

Authors:  Margaret M Marczewski; Marek Postula; Dariusz Kosior
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 9.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

10.  Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor.

Authors:  Sailaja Paruchuri; Hiroyuki Tashimo; Chunli Feng; Akiko Maekawa; Wei Xing; Yongfeng Jiang; Yoshihide Kanaoka; Pamela Conley; Joshua A Boyce
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.